Omeat
Ali Khademhosseini is the CEO and Director of Terasaki Institute for Biomedical Innovation, a research organization focused on enabling translational science and academic entrepreneurship. Ali is also the Founder and CEO of Omeat. Previously, Ali was a Co-Founder and Board member of Obsidio, Inc., a company that developed FDA cleared embolic material and was later sold to Boston Scientific. With a background in bioengineering and biomedical engineering, Ali has held various prestigious academic positions at institutions such as Harvard University, University of California, Los Angeles, and Massachusetts Institute of Technology.
This person is not in any teams
Omeat
Omeat is a food startup that has pioneered a scalable way to produce cultivated meat that’s delicious, affordable, orders-of-magnitude more sustainable than conventional meat, and doesn’t involve sacrificing an animal. The secret to Omeat is a proprietary process that harnesses the intrinsically regenerative factors within cows' plasma to foster cell growth. Omeat’s growth media is a cost-effective alternative to fetal bovine serum and can be used to cultivate any kind of meat. Omeat is based in Los Angeles, founded in 2020 by world-renown tissue biologist Dr. Ali Khademhosseini. The company is currently building a pilot plant and rapidly expanding its team toward commercial readiness.